Indeed, our work is consistent with recent studies which showed that PARP inhibitor resistant cells upregulate ALDH1A1 and that co-treatment of ovarian cancer cells with the PARP inhibitor olaparib and an ALDH1A1 inhibitor, resulted in synergistic killing of ovarian cancer cells carrying BRCA2 mutation 33. Here, ALDH1A1 is linked to ovarian carcinoma.